

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KELUN-BIOTECH**  
**科伦博泰**

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**

**四川科倫博泰生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6990)**

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING  
HELD ON DECEMBER 31, 2025**

Reference are made to the notice and circular (the “**Circular**”) of the extraordinary general meeting (the “**EGM**”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) dated December 15, 2025. Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Circular.

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce the poll results of the EGM held at 9:00 a.m. on December 31, 2025 at Meeting Room 1, 2/F, K1 Building, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu, Sichuan Province, the People's Republic of China.

## Poll Results of Resolutions Proposed at the EGM

Resolutions of the EGM were voted on by poll. The voting results of the resolutions proposed at the EGM are as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the continuing connected transactions under the 2026 Promotional Services Framework Agreement.	21,558,838 (99.990260%)	0 (0.000000%)	2,100 (0.009740%)
2.	To consider and approve the continuing connected transactions under the 2026 Auxiliary R&D Services Framework Agreement.	21,558,838 (99.990260%)	0 (0.000000%)	2,100 (0.009740%)
3.	To consider and approve the continuing connected transactions under the 2026 Procurement and Sale of Equipment and Materials Framework Agreement.	21,558,838 (99.990260%)	0 (0.000000%)	2,100 (0.009740%)

SPECIAL RESOLUTIONS		Number of Votes (%)		
		For	Against	Abstain
1.	To approve and adopt the 2025 Share Incentive Scheme and authorize the Directors and its Delegate(s) to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient in order to give full effect to the 2025 Share Incentive Scheme.	173,011,354 (98.665064%)	2,338,739 (1.333738%)	2,100 (0.001198%)
2.	To approve and adopt the scheme mandate limit of the 2025 Share Incentive Scheme (being 3,500,000 H Shares).	173,046,754 (98.685252%)	2,303,339 (1.313550%)	2,100 (0.001198%)

*Notes:*

- (a) 3 Shareholders (or their proxies) attended the EGM and held 175,352,193 Shares in aggregate.
- (b) As more than one-half of the votes were cast in favour of ordinary resolutions 1 to 3 of the EGM, the said resolutions were duly passed as ordinary resolutions of the Company.
- (c) As above two-thirds of the votes were cast in favour of special resolutions 1 and 2 of the EGM, the said resolutions were duly passed as special resolutions of the Company.
- (d) As at the date of the EGM, the total number of issued Shares of the Company was 233,185,969 Shares, consisting of (i) 70,415,990 Unlisted Shares, comprising 65,773,800 Domestic Shares and 4,642,190 Unlisted Foreign Shares, and (ii) 162,769,979 H Shares.
- (e) Each of Kelun Pharmaceutical, Mr. LIU Gexin, Dr. GE Junyou, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and their respective associates who have material interests in the CCT Agreements is required to abstain and did abstain from voting on the resolutions regarding the CCT Agreements at the EGM. As at the date of the EGM, Kelun Pharmaceutical and its associates held 153,791,255 Shares of the Company (consisting of 62,201,712 Unlisted Shares and 91,589,543 H Shares), representing approximately 65.95% of the total issued share capital of the Company, and the equity interest in the Company held by each of Mr. LIU Gexin, Dr. GE Junyou, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao and Ms. LIAO Yihong were all held through Kelun Pharmaceutical and/or its associates. Accordingly, the total number of Shares of the Company entitling the holders to attend and vote on ordinary resolutions 1 to 3 at the EGM was 79,394,714 Shares (consisting of 8,214,278 Unlisted Shares and 71,180,436 H Shares), representing approximately 34.05% of the total issued share capital of the Company. Shareholders (or their proxies) attending the EGM held 21,560,938 Shares in aggregate entitling them to vote on ordinary resolutions 1 to 3, representing approximately 27.156642% of the total number of Shares of the Company entitling the holders to attend and vote on such resolutions.
- (f) The total number of Shares of the Company entitling the holders to attend and vote on special resolutions 1 and 2 at the EGM was 233,185,969 Shares, consisting of 70,415,990 Unlisted Shares and 162,769,979 H Shares. Shareholders (or their proxies) attending the EGM held 175,352,193 Shares in aggregate entitling them to vote on special resolutions 1 and 2, representing approximately 75.198432% of the total number of Shares of the Company entitling the holders to attend and vote on such resolutions.
- (g) None of the Shares of the Company entitling the holders to attend the EGM required the holders to abstain from voting in favour of the resolutions pursuant to Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
- (h) Save as disclosed above, none of the Shareholders of the Company have stated their intention in the Circular to vote against or abstain from voting on any of the resolutions at the EGM.
- (i) The convening of and the procedure for the holding of the EGM was in compliance with the requirements of PRC laws, administrative regulations and the Articles of Association.

- (j) The H Share Registrar of the Company, Computershare Hong Kong Investor Services Limited, two representatives of the Shareholders and a representative of the Supervisors acted as the counters and scrutineers for the vote-taking at the EGM.
- (k) The following Directors of the Company attended the EGM either in person or through video or teleconference: Mr. LIU Gexin, chairman of the Board and non-executive Director; Dr. GE Junyou, executive Director; Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo, non-executive Directors; and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong, independent non-executive Directors.

By order of the Board  
**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**LIU Gexin**  
*Chairman of the Board and Non-executive Director*

Hong Kong, December 31, 2025

*As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping, and Dr. LI Yuedong as independent non-executive Directors.*